These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 3276632)

  • 21. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.
    Jacobs TW; Prioleau JE; Stillman IE; Schnitt SJ
    J Natl Cancer Inst; 1996 Aug; 88(15):1054-9. PubMed ID: 8683636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epithelial growth factor receptors (EGF-R) and DNA flow cytometry in addition to lymph node and hormone receptor status as prognostic factors in primary breast cancer].
    Costa SD; Kaufmann M; Fabbro D; Tokus M; Feichter G; Klinga K; Bastert G
    Geburtshilfe Frauenheilkd; 1989 Apr; 49(4):375-8. PubMed ID: 2544476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma.
    Bozzetti C; Nizzoli R; Naldi N; Manotti L; Savoldi L; Camisa R; Guazzi A; Cocconi G
    Breast Cancer Res Treat; 1994; 32(2):221-8. PubMed ID: 7865851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 quantitative immunocytochemical analysis in breast carcinomas.
    Charpin C; DeVictor B; Andrac L; Amabile J; Bergeret D; LaVaut MN; Allasia C; Piana L
    Hum Pathol; 1995 Feb; 26(2):159-66. PubMed ID: 7860046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast.
    Nouman GS; Anderson JJ; Crosier S; Shrimankar J; Lunec J; Angus B
    J Clin Pathol; 2003 Jul; 56(7):507-11. PubMed ID: 12835295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
    Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
    Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer.
    Mørkve O; Halvorsen OJ; Stangeland L; Gulsvik A; Laerum OD
    Int J Cancer; 1992 Dec; 52(6):851-5. PubMed ID: 1334053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
    Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
    APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
    Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
    Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
    Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
    Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
    Weikel W; Beck T; Rosenthal H; Herzog R
    Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):277-82. PubMed ID: 2566552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
    Bol MG; Baak JP; van Diermen B; Buhr-Wildhagen S; Janssen EA; Kjellevold KH; Kruse AJ; Mestad O; Øgreid P
    J Clin Pathol; 2003 Jun; 56(6):447-52. PubMed ID: 12783972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.